First Look at Control-IQ: A New-Generation Automated Insulin Delivery System
Sue Brown, Dan Raghinaru, Emma Emory, Boris Kovatchev, Sue Brown, Dan Raghinaru, Emma Emory, Boris Kovatchev
Abstract
Objective: To pilot test a new closed-loop control technology to validate it for a further large clinical trial.
Research design and methods: The t:slim X2 insulin pump with Control-IQ Technology (Tandem Diabetes Care) includes a Dexcom G6 sensor and a closed-loop algorithm implemented in the pump that 1) automates insulin correction boluses, 2) has a dedicated hypoglycemia safety system, and 3) gradually intensifies control overnight, aiming for blood glucose levels of approximately 100-120 mg/dL every morning.
Results: Five patients with type 1 diabetes (mean age 52.8 years, 2/3 male/female, mean A1C 6.5%) used Control-IQ in an outpatient setting (hotel) for approximately 37 h. During the closed loop, mean glucose was 129 mg/dL (135/121 mg/dL during the day/night), time within target range 70-180 mg/dL was 87% (82%/94% during the day/night), and time <60 mg/dL was 1.1% (2.0%/0.0% during the day/night).
Conclusions: Following this pilot trial, Control-IQ was deployed in several studies, including the large-scale National Institutes of Health International Diabetes Closed-Loop (iDCL) Trial.
Trial registration: ClinicalTrials.gov NCT03368937.
© 2018 by the American Diabetes Association.
Source: PubMed